We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
- Authors
Grani, Giorgio; Lamartina, Livia; Alfò, Marco; Ramundo, Valeria; Falcone, Rosa; Giacomelli, Laura; Biffoni, Marco; Filetti, Sebastiano; Durante, Cosimo
- Abstract
<bold>Context: </bold>Current guidelines recommend a selective use of radioiodine treatment (RAI) for papillary thyroid cancer (PTC).<bold>Objective: </bold>This work aimed to determine how policy changes affect the use of RAI and the short-term outcomes of patients.<bold>Methods: </bold>A retrospective analysis of longitudinal data was conducted in an academic referral center of patients with nonaggressive PTC variants; no extrathyroidal invasion or limited to soft tissues, no distant metastases, and 5 or fewer central-compartment cervical lymph node metastases. In cohort 1, standard treatments were total thyroidectomy and RAI (May 2005-June 2011); in cohort 2 decisions on RAI were deferred for approximately 12 months after surgery (July 2011-December 2018). Propensity score matching was used to adjust for sex, age, tumor size, lymph node status, and extrathyroidal extension. Intervention included immediate RAI or deferred choice. Main outcome measures were responses to initial treatment during 3 or more years of follow-up.<bold>Results: </bold>In cohort 1, RAI was performed in 50 of 116 patients (51.7%), whereas in cohort 2, it was far less frequent: immediately in 10 of 156 (6.4%), and in 3 more patients after the first follow-up data. The frequencies of structural incomplete response were low (1%-3%), and there were no differences between the 2 cohorts at any follow-up visit. Cohort 2 patients had higher rates of "gray-zone responses" (biochemical incomplete or indeterminate response).<bold>Conclusion: </bold>Selective use of RAI increases the rate of patients with "uncertain" status during early follow-up. The rate of structural incomplete responses remains low regardless of whether RAI is used immediately. Patients should be made aware of the advantages and drawbacks of omitting RAI.
- Subjects
THYROID cancer; IODINE isotopes; RESEARCH; THYROID gland tumors; RESEARCH methodology; CANCER relapse; RETROSPECTIVE studies; MEDICAL cooperation; EVALUATION research; IODINE radioisotopes; TREATMENT effectiveness; COMPARATIVE studies
- Publication
Journal of Clinical Endocrinology & Metabolism, 2021, Vol 106, Issue 4, pe1717
- ISSN
0021-972X
- Publication type
journal article
- DOI
10.1210/clinem/dgaa973